triazoles has been researched along with ifosfamide in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M | 1 |
Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ | 1 |
1 trial(s) available for triazoles and ifosfamide
Article | Year |
---|---|
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Etoposide; Humans; Hydrazines; Ifosfamide; Lymphoma, T-Cell; Neoplasm Recurrence, Local; Triazoles | 2021 |
2 other study(ies) available for triazoles and ifosfamide
Article | Year |
---|---|
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Etoposide; Female; Humans; Ifosfamide; Immunotherapy; Interleukin-2; Isotretinoin; Leuprolide; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Triazoles; Triple Negative Breast Neoplasms | 2015 |